
Nasdaq: VRTXVertex Pharmaceuticals
Vertex Pharmaceuticals Q3 2026 Results: Net Income $654 Million on Revenue of $3.44 Billion
Vertex Pharmaceuticals (Nasdaq: VRTX) reported third quarter 2026 GAAP revenue of $3.44 billion and GAAP net income of $653.6 million, and it said on 2 Nov 2026 that the results cover the three months to 30 Sep 2026. GAAP diluted EPS was $2.56, and the company's adjusted diluted EPS, a company-defined measure that excludes items such as stock-based compensation, was $4.76.
- US stocks
- Earnings